Review of long term immunogenicity and tolerability of live hepatitis A vaccine
Hepatitis A represents one of the major public health problems worldwide including India. Vaccination is the most effective way to prevent hepatitis A infection. Two types of hepatitis A vaccines-live attenuated (H2 strain) and inactivated (killed) are available for use in clinical practice in India...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2020-11-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/21645515.2020.1741997 |
| _version_ | 1797677256862072832 |
|---|---|
| author | Nitin Shah MMA Faridi Monjori Mitra Ashish Bavdekar Archana Karadkhele Gaurav Puppalwar Rishi Jain |
| author_facet | Nitin Shah MMA Faridi Monjori Mitra Ashish Bavdekar Archana Karadkhele Gaurav Puppalwar Rishi Jain |
| author_sort | Nitin Shah |
| collection | DOAJ |
| description | Hepatitis A represents one of the major public health problems worldwide including India. Vaccination is the most effective way to prevent hepatitis A infection. Two types of hepatitis A vaccines-live attenuated (H2 strain) and inactivated (killed) are available for use in clinical practice in India with former having advantage of a single-dose compared to two-dose killed vaccine. One of the important characteristic of an ideal vaccine includes its ability to provide life-long protection. In this article we reviewed the available long-term (≥10 years follow-up) published data on live attenuated hepatitis A (H2 strain) vaccine. The data from country of origin of the vaccine (China) and India establish the long-term immunogenicity, protection, and tolerability. Based on the results of several clinical trials showing long-term protection, single dose of live attenuated hepatitis vaccine can be widely used to protect high-risk population against hepatitis A virus infection and related complications. |
| first_indexed | 2024-03-11T22:42:54Z |
| format | Article |
| id | doaj.art-0dbe5bfb29d541c28ac29ea5842e1758 |
| institution | Directory Open Access Journal |
| issn | 2164-5515 2164-554X |
| language | English |
| last_indexed | 2024-03-11T22:42:54Z |
| publishDate | 2020-11-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj.art-0dbe5bfb29d541c28ac29ea5842e17582023-09-22T08:51:48ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2020-11-0116112816282110.1080/21645515.2020.17419971741997Review of long term immunogenicity and tolerability of live hepatitis A vaccineNitin Shah0MMA Faridi1Monjori Mitra2Ashish Bavdekar3Archana Karadkhele4Gaurav Puppalwar5Rishi Jain6PD Hinduja HospitalERA’s Lucknow Medical College & HospitalInstitute of Child HealthKEM HospitalWockhardt LtdWockhardt LtdWockhardt LtdHepatitis A represents one of the major public health problems worldwide including India. Vaccination is the most effective way to prevent hepatitis A infection. Two types of hepatitis A vaccines-live attenuated (H2 strain) and inactivated (killed) are available for use in clinical practice in India with former having advantage of a single-dose compared to two-dose killed vaccine. One of the important characteristic of an ideal vaccine includes its ability to provide life-long protection. In this article we reviewed the available long-term (≥10 years follow-up) published data on live attenuated hepatitis A (H2 strain) vaccine. The data from country of origin of the vaccine (China) and India establish the long-term immunogenicity, protection, and tolerability. Based on the results of several clinical trials showing long-term protection, single dose of live attenuated hepatitis vaccine can be widely used to protect high-risk population against hepatitis A virus infection and related complications.http://dx.doi.org/10.1080/21645515.2020.1741997hepatitis a vaccinehepatitis a vaccineimmunogenicitylive attenuatedtolerability |
| spellingShingle | Nitin Shah MMA Faridi Monjori Mitra Ashish Bavdekar Archana Karadkhele Gaurav Puppalwar Rishi Jain Review of long term immunogenicity and tolerability of live hepatitis A vaccine Human Vaccines & Immunotherapeutics hepatitis a vaccine hepatitis a vaccine immunogenicity live attenuated tolerability |
| title | Review of long term immunogenicity and tolerability of live hepatitis A vaccine |
| title_full | Review of long term immunogenicity and tolerability of live hepatitis A vaccine |
| title_fullStr | Review of long term immunogenicity and tolerability of live hepatitis A vaccine |
| title_full_unstemmed | Review of long term immunogenicity and tolerability of live hepatitis A vaccine |
| title_short | Review of long term immunogenicity and tolerability of live hepatitis A vaccine |
| title_sort | review of long term immunogenicity and tolerability of live hepatitis a vaccine |
| topic | hepatitis a vaccine hepatitis a vaccine immunogenicity live attenuated tolerability |
| url | http://dx.doi.org/10.1080/21645515.2020.1741997 |
| work_keys_str_mv | AT nitinshah reviewoflongtermimmunogenicityandtolerabilityoflivehepatitisavaccine AT mmafaridi reviewoflongtermimmunogenicityandtolerabilityoflivehepatitisavaccine AT monjorimitra reviewoflongtermimmunogenicityandtolerabilityoflivehepatitisavaccine AT ashishbavdekar reviewoflongtermimmunogenicityandtolerabilityoflivehepatitisavaccine AT archanakaradkhele reviewoflongtermimmunogenicityandtolerabilityoflivehepatitisavaccine AT gauravpuppalwar reviewoflongtermimmunogenicityandtolerabilityoflivehepatitisavaccine AT rishijain reviewoflongtermimmunogenicityandtolerabilityoflivehepatitisavaccine |